Invesaro

Stocks FDUS Financial statements

Financial statements

FIDUS INVESTMENT Corp financial statements

Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data FIDUS INVESTMENT Corp files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2020FY2022FY2022FY2023FY2024FY2025
Operating expenses456546.564.369.3
Interest expense17.416.916.620.622.328.8
Income tax0.860.511.411.032.44
Net income31.295.2-10.512.178.382.4
EPS, basic1.621.031.902.472.292.08
EPS, diluted1.621.031.902.472.292.08
Shares, basic (weighted)24.424.424.526.432.635.5
Shares, diluted (weighted)24.424.424.526.432.635.5
Dividend per share1.331.602.002.882.422.15

Balance sheet

FY2020FY2022FY2022FY2023FY2024FY2025
Cash and equivalents16962.411957.270
Total assets8979361,0911,1641,427
Total liabilities409456501508685
Total debt420476484658
Paid-in capital362396504567641
Retained earnings12684.485.488.5100
Shareholders' equity411488480589656742
Total equity411488480589656742
Total liabilities and equity8979361,0911,1641,427
Shares outstanding24.424.730.433.938

Cash flow statement

FY2020FY2022FY2022FY2023FY2024FY2025
Net income31.235.835.877.178.382.4
Cash from operations56-106-106-29.5-55.3-147
Purchases of investments-190-347-334-337-395-498
Debt issued200
Debt repaid-125
Share buybacks-0.27
Cash from financing53.3-1.53-1.5386.2-6.67169
Net change in cash109-107-10756.8-6222.4
Interest paid17.416.516.519.422.427.2
Income taxes paid1.714.294.2911.43.34.56

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $19.15 on September 25, 2026.

Profitability

MetricValueHow it is calculated
Return on equity (ROE)10.5%Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)5.1%Net income / average total assets.

Growth

MetricValueHow it is calculated
Net income growth, 1y5.2%Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 5y21.4%Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y-9.2%EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y3.1%Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y5.1%Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Dividend per share growth, 1y-11.2%Dividend per share vs the same period a year earlier. Only from a positive base.
Dividend per share CAGR, 3y2.4%Compound annual growth of dividend per share over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Dividend per share CAGR, 5y10.1%Compound annual growth of dividend per share over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y13.2%Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y15.6%Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y12.6%Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y22.5%Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y15.1%Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y8.9%Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y13.2%Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y7.7%Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

MetricValueHow it is calculated
Debt / equity1.00xTotal debt / shareholders' equity. Not shown when equity is negative.
Debt / assets49.3%Total debt / total assets.
Liabilities / assets50.8%Total liabilities / total assets.
Net debt$702.2MTotal debt - cash - short-term investments. Negative means more cash than debt.
Tangible book value$738.5MShareholders' equity - goodwill - intangible assets.

Per share

MetricValueHow it is calculated
EPS, diluted$2.16Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share-$5.57Cash from operations / diluted weighted shares.
Book value per share$19.46Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share$19.46Tangible book value / shares outstanding.
Cash per share$0.99(Cash + short-term investments) / shares outstanding.

Valuation

MetricValueHow it is calculated
Market cap$726.8MShare price x shares outstanding.
Enterprise value$1.43BMarket cap + total debt - cash - short-term investments.
P/E9.40xMarket cap / net income. Only when net income is positive.
P/B0.98xMarket cap / shareholders' equity. Only when equity is positive.
Price / tangible book0.98xMarket cap / tangible book value, when positive.
Earnings yield10.6%Net income / market cap (the inverse of P/E).
PEG3.07xP/E / EPS growth per year over 3 years (in percent). Only when both are positive.
Was FIDUS INVESTMENT Corp profitable in fiscal 2025?

Yes. Net income was $82.4M, a net margin of -.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to FIDUS INVESTMENT Corp